Medical Newswire

Medical Newswire!

Medicine, Healthcare, Medical Research, Hospitals, Management
Press release distribution service
Home | Medical-Newswire.Com:

VFC's Stock House: Buyout Talk, Catalysts And Clinical Results Can Move These Health Care Stocks

(Medical-NewsWire.com, July 12, 2012 ) New York, NY -- VFC's Stock House, an information and research outlet that brings ideas and opens discussions to a broad spectrum of investors, brings attention to some companies that may be worth keeping an eye on as the merger and acquisition market in the biotech and pharmaceutical sectors heat up.



Trial results, trial initiations, FDA approval filings, peer-reviewed validation and FDA approvals are all factors that play heavily into the trading patterns of biotech and healthcare companies looking to make a mark in the sector. This is especially true for the relatively small cap, developmental companies that are dependant upon catalyst event that could propel to the 'next level,' so to say, which would launch them into the mainstream of the investing community and also potentially throw them on the radar as a possible buyout or partnership target of a larger pharmaceutical company.



Given the recent string of high-profile acquisitions and takeover offers, whether they be hostile or not, many still-developmental companies - and some, like Amarin Corp (AMRN), who are swiftly nearing the commercialization stage - openly declare themselves as 'on the block' to accept offers for an outright purchase.



It's a seller's market right now, meaning if you've got a product to sell that could potentially replace some glaring gaps that have opened up in the big pharma pipeline as the result of a slew of patent expirations, then you're holding the leverage to hold out and wait for the best deal. Take some recent examples as evidence; GlaxoSmith (GSK), for instance, made international headlines with an offer to acquire Human Genome Sciences (HGSI). That bid has since gone hostile when Human Genome demanded a better deal. Illumina Inc. (ILMN) also rejected two offers from Roche Holding AG (RHHBY.PK) -- one for $44.50/share and the other for $51/share -- and Amylin Pharmaceuticals (AMLN) turned away Bristol-Myers Squibb Company (BMY) earlier this year on a $3.5 billion, $22/share offer.



Prolor Biotech (PBTH), with potentially catalysts on the not-so-distant horizon, is one such company that may fit into the 'buyout target' profile. Prolor holds world wide rights to the naturally-occurring Carboxyl Terminal Peptide (CTP), which can be attached to already-existing therapeutic proteins in order to slow the process by which the protein is removed from the human body and thereby creating an extended life span for an already-existing treatment. This process significantly reduces the amount of injections or applications a patient would need to endure during the course of treatment.



The company has yet another catalyst pending with the initiation of Phase III trial in adults later this year. Success in that trial would likely lead to a nice runup as Prolor would then look for approvals - if the company is not bought out beforehand.



Although most larger companies generally wait until approval decisions are known before buying-in, Teva's (TEVA) Dr. Phillip Frost is already heavily invested in PBTH and could throw an offer on the table with a decision still pending, assuming positive clincal results.



Another company that may be in line to receive an offer before the approval process is complete is Lpath Inc. (LPTN). Considering the potential catalysts in play and a prime-time partnership with Pfizer (PFE), Lpath shares may be undervalued right now.



Lpath has become a recognized leader in the field of developing lipid-based therapies through its proprietary ImmuneY2 platform, which contains the ability to generate therapeutic antibodies that bind to and inhibit bioactive lipids that contribute to the spreading and growth of various diseases and inflammatory/auto-immune disorders. The market potential for this technology in treating a plethora of modern day illnesses and diseases, should it advance past the clinical stages, is huge. Lpath is first applying this technology to treat Wet AMD and cancer, both multi-billion dollar markets, and that could just be the beginning.



Sunshine Heart (SSH), for example, saw its share price explode over the past few trading sessions on the potential of its implantable device to treat Class III and ambulatory Class IV heart failure. The company could register its first sales later this year and also has the initiation of a pivotal US trial on the table for later this year as another potential catalyst.



MRI Interventions (MRIC) is another company whose share price has registered some nice recent gains as its MRI-enhancing device, ClearPoint, allows the medical community to conduct less-invasive procedures on the brain. MRIC is also developing its ClearTrace system to augment existing MRI suites to conduct less-invasive procedures of the heart and Siemens AG (SI) is already on board as a partner for its development. Another unique collaboration with Boston Scientific Corporation (BSX) identifies this company as a buyout play, once again.



Cytosorbents, Inc (CTSO) is also one not to ignore in the medical device sector, as this company recently announced the official commercial launch of its blood purification CytoSorb device, destined to treat severe sepsis and other indications where high cytokines are present. The device was approved in Europe on results strong enough that European regulators did not even wait for final data to be compiled before rendering their decision. It also helped that CytoSorb targets a market for which there are currently no effective treatments. Additional trials in the US are in the preparatory stages.



For full report visit: http://vfcsstockhouse.com/blog/article/-buyout-talk-catalysts-and-clinical-results-can-move-these-health-care-stocks



For this week's list of hot stocks to watch visit: http://vfcsstockhouse.com/blog/article/-weekly-stock-watch-week-of-july-9-jpm-aa-goog-ssh-mnkd-mric-sppi-jazz-pbth-teva-mrk-lptn-pfe-gnbt-ctso-tlle-fb-yhoo-imsc



Contact VFC's Stock House: vfc@vfcsstockhouse.com



Originally published at: http://vfcsstockhouse.com



Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse



'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213



About VFCsStockHouse.com:



VFC's Stock House is an information and research outlet that brings new ideas to the table and opens discussions for a broad spectrum of investors, with a strong focus on - but not limited to - biotech stocks, biopharma stocks, growth stocks and the pharmaceutical and healthcare sectors. VFC's Stock House provides individual company profiles, write-ups and reports as well as giving general insights into broader-market news through various 'Stock Watch' lists. At the conclusion of most weeks, VFC's Stock House issues a "Weekly Stock Watch" that examines news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. The information contained within the pages of VFC’s Stock House are not intended to be taken as advice, but as a starting point where investors can follow up with their own DD and devise their own entry and exit strategies.



For full disclaimer visit: http://vfcsstockhouse.com





VFC's Stock House

VFC

240-786-2111

vfc@vfcsstockhouse.com

Source: EmailWire.Com

Source: EmailWire.com


Medical Resources
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Healthcare resource center today to browse our selection of 600+ complimentary Healthcare magazines, white papers, webinars, podcasts, and more. Get popular titles including:

Eyecare Business
Medical Laboratory Observer
FierceHealthcare

No credit cards, coupons, or promo codes required. Try it today!

Medical Sponsors

Health News
Health News Headlines - Yahoo! News
Health News Headlines - Yahoo! News
Get the latest health news headlines from Yahoo! News. Find breaking health news, including analysis and opinion on top health stories.

WHO says single yellow fever shot is enough
17 May 2013 at 2:10am
GENEVA (AP) ? The World Health Organization says a yellow fever booster vaccination given 10 years after the initial shot isn't necessary.


Tiny preemies get a boost from live music therapy
16 May 2013 at 1:16am

CHICAGO (AP) ? As the guitarist strums and softly sings a lullaby in Spanish, tiny Augustin Morales stops squirming in his hospital crib and closes his eyes.


Correction: New Virus story
16 May 2013 at 12:05pm
NEW YORK (AP) ? In a story May 15 about a new SARS-like virus spreading from patients to health care workers in Saudi Arabia, The Associated Press reported erroneously the location of the 20 deaths attributed to the virus. There have been no deaths reported in France and Qatar, only in Saudi Arabia, Jordan, Germany and Britain.


Greying China taps rural elderly to care for those even older
18 May 2013 at 9:18pm

By Li Hui and Maxim Duncan QIANTUN, China (Reuters) - Two years short of 70, Zhang Guosheng spends his days caring for an 81-year-old fellow villager - washing his clothes, bringing meals to his bed, and keeping him company - a routine he'll keep up until he himself needs the type of care he is now giving. "Living here is better than staying at home alone. We help each other and have a common language," said the spritely Zhang, an enthusiastic dancer. "We are very happy here. ...


Saudi Arabia has another case of new coronavirus: WHO
18 May 2013 at 2:42pm
LONDON (Reuters) - Saudi Arabia has reported another case of infection in a concentrated outbreak of a new strain of a virus that emerged in the Middle East last year and spread into Europe, the World Health Organization (WHO) said on Saturday. In a disease outbreak update issued from its Geneva headquarters, the WHO said the latest patient is an 81-year-old woman with multiple medical conditions. She became ill on April 28 and is in a critical but stable condition. ...

Lundbeck says drug shows improvement in depression symptoms
18 May 2013 at 11:05am
COPENHAGEN (Reuters) - Danish pharmaceutical group Lundbeck and Japanese partner Takeda said on Saturday that data from clinical phase III studies with the antidepressant vortioxetine had shown significant improvement in patients' symptoms. Lundbeck said in a statement that the trial showed safety levels consistent with previously completed studies at lower doses. Lundbeck and Takeda submitted vortioxetine, also known as Brintellix, for regulatory approval in the United States and Europe at the end of last year. ...

Men Struggle With Wives' Breast Cancer
18 May 2013 at 8:59am
Men struggle with their wives' breast cancer, but don't always speak up.        


Bernanke upbeat on innovation outlook in commencement address
18 May 2013 at 8:14am

WASHINGTON (Reuters) - Federal Reserve Chairman Ben Bernanke painted an upbeat picture on Saturday for the potential of innovation to lift living standards, delivering a sweeping look at the last 100 years that included memories of his 1963 South Carolina home. Bernanke made no reference to monetary policy or the immediate outlook for the U.S. economy in prepared remarks to graduates of Bard College at Simon's Rock, Massachusetts. But the die-hard baseball fan did manage to work in a reference to one of the sport's greats. ...



Afghan parliament fails to pass divisive women's law
18 May 2013 at 4:51am

By Miriam Arghandiwal and Ibrahimi Aziz KABUL (Reuters) - Afghanistan's parliament failed to pass a law on Saturday banning violence against women, a severe blow to progress made in women's rights in the conservative Muslim country since the Islamist Taliban was toppled over a decade ago. President Hamid Karzai approved the law by decree in 2009 and parliament's endorsement was required. But a rift between conservative and more secular members of the assembly resulted in debate being deferred to a later date. ...


Men Struggle With Wives' Breast Cancer, Too
18 May 2013 at 3:08am
Men struggle with their wives' breast cancer, but don't always speak up.        


Flesh-eating disease victim gets prosthetic hands
17 May 2013 at 7:12pm

ATLANTA (AP) ? A metro Atlanta woman who lost both hands, her left leg and right foot after contracting a flesh-eating disease was on her way back from Ohio Friday after being fitted with prosthetic hands.



OAS calls for softer approach toward illegal drug users
17 May 2013 at 3:09pm

By Eduardo Garcia BOGOTA (Reuters) - The Organization of American States on Friday published a report calling for decriminalization of drug use and for greater coordination between nations in tackling the scourge. "The report presented by the OAS today is a vital piece in the construction of a common way to fight this problem," Colombian President Juan Manuel Santos said during the presentation of the 200-page report in Bogota. ...


Mini-Movies May Boost IVF Success
17 May 2013 at 3:00pm
Mini-movies of growing embryos could help boost the success of in vitro fertilization, a new study found. But the number of women who could benefit from the time-lapse technology is unclear.        

Fever reducers don't slow children's recovery: study
17 May 2013 at 2:33pm
By Trevor Stokes NEW YORK (Reuters Health) - A review of past research finds that fever-reducing drugs have no effect on the speed of children's recovery from an infection, contrary to the fears of some doctors and parents. Researchers have debated for decades whether lowering a sick child's fever helps the recovery process or interferes with the body's ability to fight the infection. Some previous research has shown that giving children fever-reducing "antipyretic" medications, such as acetaminophen, after vaccinations interfered with their immune responses to the vaccines, for example. ...

Is MRSA the Godzilla of Superbugs?
17 May 2013 at 2:18pm
In the years I?ve spent writing about infectious diseases I can only think of a handful that have made me squirm: Guinea worm disease, which involves painful extractions of long worms from the human body (blech); Naegleria fowleri, the brain-eating amoeba (pretty self-explanatory); Ebola (because, well, it?s Ebola); and Staph A (full name, Staphylococcus aureus).

Pharmanewswire.com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright © GroupWeb Media LLC. All Rights Reserved.

For unlimited press release distribution for $99 per month, call (281) 645-4086 or start posting your press releases online at EmailWire.com. CityRegions.Com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright © 2012 GroupWeb Media LLC. All Rights Reserved.


GroupWeb Media Network
AfricaNewswire.Net | AppleNews247.Com | AsiaNewsWire.Net | Aviation-NewsWire | Energy Industry | EstateNewsWire | Entertainment-NewsWire.com | Food Beverage News | Glamour NewsWire | Health NewsWire | Hosting NewsWire | i-Auto NewsWire | i-Business News | EuropeNewsWire.Net | iCameroon.com | i-Canada-News.Com | i-SoftwareNews.com | iT-NewsWire.Com
| InvestorsNewsDesk.Com | i-TravelNewsWire.Com | LegalLaw247.com | Medical-NewsWire.com | MiningNewsWire.net | MoneyNewsWire.Net | Movie-Stars-News.Com | PayDayNews247.Com | PharmaNewsWire.Com | Publishing-NewsWire.Com | Shopping-NewsWire.com | Telecom-NewsWire.Net | Transportation-News.Com | USGovernment-News.Com | WebPosters.Net | Wireless-NewsWire.Com |
Medical-Newswire.com - Medicl Newswire and Press Release service of GroupWeb Media LLC